

DermaDel Standard Cuff (SC) Nitrile Exam Gloves



This product is crafted with low dermatitis potential, making it suitable for users with sensitive skin. Featuring textured fingertips, it provides improved grip and control. Made from medical-grade materials, it meets a stringent AQL 1.5 standard for high quality and durability. The gloves are ambidextrous for easy use on either hand, non-sterile, and powder-free to minimize the risk of contamination. Chlorinated for easy donning, these gloves are designed for single-use applications with a standard cuff length of 9.5 inches for a comfortable fit.

Features and Benefits

- **9.5" Standard Cuff** – Provides secure wrist coverage for everyday medical use.
- **Low Dermatitis Potential** – Reduces skin irritation, making it ideal for prolonged wear.
- **Textured Fingertips** – Enhances grip for precise handling in wet and dry conditions.
- **Medical-Grade & AQL 1.5** – Ensures top-tier quality, safety, and reliability in healthcare settings.
- **Powder-Free & Latex-Free** – Prevents contamination and allergic reactions.
- **Tested for Chemotherapy Drugs** – Offers resistance against hazardous substances for enhanced safety.

Reference No.	Description	Quantity	Product Specifications (ASTM 6319)		
DDMD01-SC	DermaDel Standard Cuff-XS	100/BX 10BX/CS	Finger Thickness (mil)	5.5	
DDMD02-SC	DermaDel Standard Cuff-S	100/BX 10BX/CS	Palm Thickness (Center of palm) (mil)	4.3	
DDMD03-SC	DermaDel Standard Cuff-M	100/BX 10BX/CS	Length (inches)	9.5"	
DDMD04-SC	DermaDel Standard Cuff-L	100/BX 10BX/CS	Physical Properties (ASTM 6319)		
DDMD05-SC	DermaDel Standard Cuff-XL	100/BX 10BX/CS	Elongation at break (%)	Unaged	Aged
			Tensile Strength (MPa)	Min. 18	Min. 14
			Force at Break (N)	Min. 6.0	Min. 6.0



Tested for use with Chemotherapy Drugs as per ASTM D6978-05:

The following chemotherapy drugs and concentration had NO Breakthrough detected up to 240 minutes:

Bendamustine HCl (Treanda) (5 mg/ml)	Docetaxel (Taxotere) (20 mg/ml)	Oxaliplatin (5 mg/ml)
Bleomycin Sulfate (15 mg/ml)	Doxorubicin Hydrochloride (2 mg/ml)	Paclitaxel (Taxol) (6 mg/ml)
Busulfan (6 mg/ml)	Epirubicin HCl (Ellence) (2 mg/ml)	Pemetrexed (25 mg/ml)
Carboplatin (10 mg/ml)	Etoposide (20 mg/ml)	Raltitrexed (0.5 mg/ml)
Carfilzomib (2 mg/ml)	Fludarabine (25 mg/ml)	Retrovir (Zidovudine) (10 mg/ml)
Cetuximab (Erbix) (2 mg/ml)	Fluorouracil (50 mg/ml)	Rituximab (10 mg/ml)
Cisplatin (1 mg/ml)	Gemcitabine (38 mg/ml)	Topotecan (1 mg/ml)
Cladribine (1 mg/ml)	Idarubicin HCl (1 mg/ml)	Trisenox (Arsenic Trioxide) (1 mg/ml)
Cyclosporin A (100 mg/ml)	Ifosfamide (50 mg/ml)	Velcade (Bortezomib) (1 mg/ml)
Cyclophosphamide (Cytosan) (20 mg/ml)	Irinotecan (20 mg/ml)	Vidaza (Azacytidine) (25 mg/ml)
Cytarabine (100 mg/ml)	Mechlorethamine HCl (1 mg/ml)	Vinblastine (1 mg/ml)
Cytovene (Ganciclovir) (10 mg/ml)	Melphalan (5 mg/ml)	Vincristine Sulfate (1 mg/ml)
Dacarbazine (DTIC) (10 mg/ml)	Methotrexate (25 mg/ml)	Vinorelbine (10 mg/ml)
Daunorubicin HCl (5 mg/ml)	Mitomycin C (0.5 mg/ml)	Zoledronic Acid (1 mg/25ml)
Decitabine (5 mg/ml)	Mitoxantrone (2 mg/ml)	

The following chemotherapy drugs and concentration showed breakthrough detected in less than 60 minutes:

Carmustine (3.3 mg/ml): 26.2 minutes Thiotepe (10.0 mg/ml): 59.1 minutes

The following hazardous drugs (opioids) and concentration had NO breakthrough detected up to 240 minutes:

Fentanyl Citrate Injection (100 mcg/2ml) Simulated Gastric Acid Fluid

